Issue №1-89, 2019

Patients rehabilitation after endometrial cancer treatment

View article (Download PDF file)



Download XML file

1 Solopova A.G., 1 Idrisova L.E., 2 Tabakman Yu.Yu.,, 1 Alipov V.I.,, 1 Chukanova E.M.

1 «I.M. Sechenov First Moscow State Medical University», Moscow, Russia
2 «Oncological clinical health center №1» of Moscow Department of Health, Moscow, Russia


ABSTRACT

Objective: To assess therapeutic and preventive effects of comprehensive medical rehabilitation program with individualrisk stratification for patients after uterine cancer treatment and impact on their quality of life.Material and Methods: The study was conducted from June 2015 to February 2018 and included 70 patients with earlystages of the uterine cancer. Half of the participants underwent the complex of medical rehabilitation and the other formedthe control group. At the beginning and in the end of the study following indicators were measured: levels of lower limblymphedema, cognitive impairment, anxiety, and depression, frequency of thrombotic events, and the quality of life. Individualassessment of the lymphedema and thrombotic event risks was performed.Results: Only in the control group patients developed the lower limb lymphedema (10 cases). Levels of cognitive impairment,anxiety, and depression were significantly lower in the experimental group (anxiety level was even lower than thebasic one). Relative risk of thrombotic events was 4.00. Patients from rehabilitation group had significantly higher quality oflife according to the EORTC QLQ-C30 questionnaire.Conclusion: Comprehensive medical rehabilitation program with individual risk stratification can significantly improvepatient quality of life after uterine cancer treatment. Long-term results can be achieved and maintained in most cases. QOLafter rehabilitation interventions can be compared to the one before cancer. In most cases it is possible to achieve and maintain,comparable to the preoperative levels.


KEYWORDS: rehabilitation, uterine cancer, cognitive impairment, psychotherapy, quality of life.



References:

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015. March 1;136(5):359-86.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
  3. Davydov MI, Aksel EM. Statistika zlokachestvennyh novoobrazovanij v Rossii i stranah SNG v 2012 g. [Statistics of malignant neoplasms in Russia and the CIS countries in 2012]. Moscow: Izdatelskaja gruppa RONC [RONTS Publishing Group]; 2014. 226p.
  4. Ballester M, Bendifallah S, Darai E. Nouvelles recommandations EMSO, ESGO, ESTRO sur la prise en charge des cancers de l’endometre [European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer]. Bull Cancer. 2017;104(12):1032-8.
  5. Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause. 2014;21(3):267-74.
  6. Filonenko EV, Demidova LV, Bojko AV, Urlova AN, Ivanova-Radkevich VI. Rehabiliation of gynecological cancer patients in the course of combined modality treatment. Journal of restorative medicine & rehabilitation 2016; 5(75):1-5
  7. Biglia N, Zanfagnin V, Daniele A, Robba E, Bounous VE. Lower Body Lymphedema in Patients with Gynecologic Cancer. Anticancer Res. 2017;37(8):4005-15.
  8. Brown JC, John GM, Segal S, Chu CS, Schmitz KH. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc. 2013;45(11):2091-7.
  9. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38(3):431-8.
  10. Zeng Y, Cheng ASK, Song T, Sheng X, Zhang Y, Liu X, Chan CCH. Subjective cognitive impairment and brain structural networks in Chinese gynaecological cancer survivors compared with age-matched controls: a cross-sectional study. BMC Cancer. 2017;17(1):796.
  11. Machida H, Hom MS, Maeda M, Yeo JJ, Ghattas CS, Grubbs BH, Matsuo K. Signs and Symptoms of Venous Thromboembolism and Survival Outcome of Endometrial Cancer. Int J Gynecol Cancer. 2016;26(5):924-32.
  12. Sekse RJ, Hufthammer KO, Vika ME. Fatigue and quality of life in women treated for various types of gynaecological cancers: a cross-sectional study. J Clin Nurs. 2015;24(3-4):546-55.
  13. Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, Wright JD, Davidson SA, Behbakht K, Flink DM. Sexual and marital dysfunction in women with gynecologic cancer. Int J Gynecol Cancer. 2017;27(3):603-7.
  14. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-9.
  15. Kuroda K, Yamamoto Y, Yanagisawa M, Kawata A, Akiba N, Suzuki K, Naritaka K. Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study. BMC Womens Health. 2017;17(1):50.
  16. Al-kindi SG, Oliveira GH. Incidence and trends of cardiovascular mortality after common cancers in young adults: Analysis of surveillance, epidemiology and end-results program. World J Cardiol. 2016;8(6):368-74.
  17. Brown JC, John GM, Segal S, Chu CS, Schmitz KH. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc. 2013;45(11):2091-7.
  18. Horowitz MA, Zunszain PA. Neuroimmune and neuroendocrine abnormalities in depression: two sides of the same coin. Ann N Y Acad Sci. 2015;1351:68-79.
  19. Fabre B, Grosman H, Gonzalez D, Machulsky NF, Repetto EM, Mesch V, Lopez MA, Mazza O, Berg G. Prostate Cancer, High Cortisol Levels and Complex Hormonal Interaction. Asian Pac J Cancer Prev. 2016;17(7):3167-71.
  20. Wolkow A, Aisbett B, Reynolds J, Ferguson SA, Main LC. Relationships between inflammatory cytokine and cortisol responses in firefighters exposed to simulated wildfire suppression work and sleep restriction. Physiol Rep. 2015;3(11).
  21. Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81-91.
  22. Qureshi W, Ali Z, Amjad W, Alirhayim Z, Farooq H, Qadir S, Khalid F, Al-Mallah MH. Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med. 2016;3:24.
  23. Gandhi AV, Mosser E, Oikonomou G, Prober DA. Melatonin is required for the circadian regulation of sleep. Neuron. 2015;85(6):1193-9.
  24. Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896-921.
  25. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102-13.
  26. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509-14.
  27. Hermelink K, Voigt V, Kaste J, Neufeld F, Wuerstlein R, Buhner M, Munzel K, Rjosk-Dendorfer D, Grandl S, Braun M, von Koch FE, Hartl K, Hasmuller S, Bauerfeind I, Debus G, Herschbach P, Harbeck N. Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst. 2015;107(7):99-111.



Creative Commons License
The content is available under the Creative Commons Attribution 4.0 License.

©

Эта статья открытого доступа по лицензии CC BY 4.0. Издательство: ФГБУ «НМИЦ РК» Минздрава России.
This is an open article under the CC BY 4.0 license. Published by the National Medical Research Center for Rehabilitation and Balneology.

Aссоциация НАЭСКЛ